
Dr Peter Wahl, MLA, MS, Global Head of Scientific Affairs at CorEvitas, part of the PPD clinical research business of Thermo Fisher Scientific, covers key considerations for choosing registries.
Dr Peter Wahl, MLA, MS, Global Head of Scientific Affairs at CorEvitas, part of the PPD clinical research business of Thermo Fisher Scientific, covers key considerations for choosing registries.
While clinical registries are a valued source of longitudinal, real-world data, registries also provide expanded options for research and advancing randomized clinical trials. Understanding when and how to use registries in these use cases is quite nuanced and mandates a targeted approach and innovative expertise. In this video, we dive deep into the expanded use of registries as external control arms in clinical trials.
As life science organizations continue to leverage both real world data [RWD] and real-world evidence [RWE] in the product approval landscape, a more nuanced understanding of both RWD and RWE is needed. Given the expansive types of data available now, understanding which data set is needed and how it should be analyzed is decidedly valuable. Our expert provides basic tenets for consideration
Published: July 31st 2023 | Updated:
Published: July 11th 2024 | Updated: